Decision to fund a new hepatitis C treatment (Maviret) and to widen access to adalimumab (Humira) for psoriasis
We are pleased to announce a decision to fund a new treatment for chronic hepatitis C infection, glecaprevir and pibrentasvir (Maviret) from 1 February 2019, and to widen access to adalimumab (Humira) for patients with psoriasis from 1 July 2019, through an agreement with AbbVie Ltd.
We’re pleased to announce a decision on how three hospital medicines (infliximab, tocilizumab and rituximab) are managed within the Pharmaceutical Schedule.
We are pleased to announce the approval of a listing agreement for a range of haemodialysis products with BSN Medical Limited.
There is a change to the 2018/19 Invitation to Tender that was issued on 1 November 2018. These amendments have been uploaded to the webpage and e-portal as relevant.
We’re pleased to announce that colecalciferol oral liquid (vitamin D3, brand name Puria) will be funded in community and hospitals without restriction from 1 January 2019.
Decision to list Interventional Radiology products supplied by Edwards Lifesciences (New Zealand) Limited
We’re pleased to announce the approval of a listing agreement for Interventional Radiology products with Edwards Lifesciences (New Zealand) Limited.
We’re pleased to announce a decision to list a new brand of iron polymaltose inj 50 mg per ml, 2 ml ampoule (Ferrosig) supplied by Sigma Healthcare.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender, dated 3 November 2016, and the 2017/18 Invitation to Tender, dated 2 November 2017.
PHARMAC has widened funded access to ceftriaxone to enable its use for the treatment of suspected meningococcal disease in the community. This change will be activated from 1 December 2018.
Decision to remove funding restrictions for alendronate 70 mg products, decrease price, and award sole supply
We’re pleased to announce that the funding restrictions on alendronate 70 mg products will be removed from 1 February 2019. At the same time, the price and subsidy of these products will decrease.
PHARMAC will not be releasing any further Requests for Proposals (RFPs) in 2018.
PHARMAC’s annual tender is an open procurement process, which offers volume gains for suppliers and reduces the requirement of brand promotion and associated costs.
An outline of the tender process stages, as well as information on how to take part in the process, is linked below.
We are pleased to announce the approval of a listing agreement for a range of interventional radiology products with Bard Australia Pty Ltd.
We’ve recently updated the Cost Resource Manual – the online list of standard costs and prices that you may find useful when preparing funding applications.
We’re pleased to announce the approval of a listing agreement for supply of needles and syringes, and respiratory equipment with REM SYSTEMS Limited.
The 2018/19 Invitation to Tender (2018/19 ITT) has been distributed today.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for one product included in the 2017/18 Invitation to Tender, dated 2 November 2017.
After reviewing the feedback on the consultation letter dated 29 August 2018 to move to one funded brand of lamotrigine (Logem), we have determined that we require additional time to consider the issues raised before a decision can be made on the proposal. At this stage we do not have a firm timeframe for when a decision will be made.
Decision to list urology, ostomy and continence products supplied by Coloplast Pty Ltd and Liberty Medical NZ Limited
We are pleased to announce the approval of non-exclusive listing agreements with Coloplast Pty Ltd and Liberty Medical NZ Limited for the supply of urology, ostomy and continence products to DHBs.
We are pleased to announce the approval of a listing agreement for a range of haemodialysis products with Defries Industries New Zealand Limited.